Journal of Clinical Oncology, Vol 21, Issue 1
(January), 2003: 78-84
© 2003 American Society for Clinical Oncology
Prognostic Factors and Clinical Outcomes in Children and Adolescents With Metastatic Rhabdomyosarcoma—A Report From the Intergroup Rhabdomyosarcoma Study IV
John C. Breneman,
Elizabeth Lyden,
Alberto S. Pappo,
Michael P. Link,
James R. Anderson,
David M. Parham,
Stephen J. Qualman,
Moody D. Wharam,
Sarah S. Donaldson,
Harold M. Maurer,
William H. Meyer,
K. Scott Baker,
Charles N. Paidas,
William M. Crist
From the Children’s Hospital Medical Center, Cincinnati, OH; University of Nebraska Medical Center, Omaha, NE; Hospital for Sick Children, Toronto, Ontario, Canada; Stanford University Medical Center, Stanford, CA; University of Arkansas, Little Rock, AR; Children’s Hospital of Columbus, Columbus, OH; Johns Hopkins Hospital, Baltimore, MD; University of Oklahoma Health Sciences Center, Oklahoma City, OK; University of Minnesota Cancer Center, Minneapolis, MN; and University of Missouri, Columbia, MO.
Address reprint requests to John C. Breneman, MD, Children’s Hospital Medical Center Cincinnati, Division of Radiation Oncology, 234 Goodman Street, ML 0757, Cincinnati OH 45219-0757, email: brenemjc{at}healthall.com, cc: smason{at}childrensoncologygroup.org.
Purpose: To identify risk factors associated with outcomes in children with metastatic rhabdomyosarcoma (RMS) treated on the fourth Intergroup Rhabdomyosarcoma Study (IRS-IV).
Patients and Methods: Patients with metastatic RMS were treated with one of two regimens that incorporated a window of either ifosfamide and etoposide (IE) with vincristine, dactinomycin, and cyclophosphamide (VAC) or vincristine, melphalan (VM) and VAC. Study end points were failure-free survival (FFS) and overall survival (OS). Clinical factors including age, histology, sites of primary and metastatic disease, and number of sites of metastatic disease were correlated with those end points.
Results: One hundred twenty-seven patients were eligible for analysis. The estimated 3-year OS and FFS for all patients were 39% and 25%, respectively. By univariate analysis, 3-year OS was significantly influenced by histology (47% for embryonal v 34% for all others, P = .026) and increasing number of metastatic sites (P = .028). By multivariate analysis, the presence of two or fewer metastatic sites was the only significant predictor (P = .007 and .006, respectively). The combination of embryonal histology with two or fewer metastatic sites identified a subgroup with 3-year FFS of 40% and OS of 47%.
Conclusion: Children with group IV RMS treated on the IRS-IV study had improved OS and FFS if they had two or fewer metastatic sites and embryonal histology. This favorable subset of patients has outcomes approaching those observed in selected patients with localized, nonmetastatic disease. Thus, these patients might not be appropriate candidates for regimens that include experimental agents with substantial toxicities or unproven antitumor activity.
Supported by Department of Health and Human Services (Washington, DC), United States Public Health Service grants no. CA-24507, CA-30138, CA-30969, CA-29139, CA-13539.
 CiteULike  Complore  Connotea  Del.icio.us  Digg  Facebook  Reddit  Technorati  Twitter What's this?
This article has been cited by other articles:
|
|
|
|
 
E. Davicioni, M. J. Anderson, F. G. Finckenstein, J. C. Lynch, S. J. Qualman, H. Shimada, D. E. Schofield, J. D. Buckley, W. H. Meyer, P. H.B. Sorensen, et al.
Molecular Classification of Rhabdomyosarcoma--Genotypic and Phenotypic Determinants of Diagnosis: A Report from the Children's Oncology Group
Am. J. Pathol.,
February 1, 2009;
174(2):
550 - 564.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
Y.-X. Ren, F. G. Finckenstein, D. A. Abdueva, V. Shahbazian, B. Chung, K. I. Weinberg, T. J. Triche, H. Shimada, and M. J. Anderson
Mouse Mesenchymal Stem Cells Expressing PAX-FKHR Form Alveolar Rhabdomyosarcomas by Cooperating with Secondary Mutations
Cancer Res.,
August 15, 2008;
68(16):
6587 - 6597.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. L. Mackall, E. H. Rhee, E. J. Read, H. M. Khuu, S. F. Leitman, D. Bernstein, M. Tesso, L. M. Long, D. Grindler, M. Merino, et al.
A Pilot Study of Consolidative Immunotherapy in Patients with High-Risk Pediatric Sarcomas
Clin. Cancer Res.,
August 1, 2008;
14(15):
4850 - 4858.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Diomedi-Camassei, H. P. McDowell, M. A. De Ioris, S. Uccini, P. Altavista, G. Raschella, R. Vitali, O. Mannarino, L. De Sio, D. A. Cozzi, et al.
Clinical Significance of CXC Chemokine Receptor-4 and c-Met in Childhood Rhabdomyosarcoma
Clin. Cancer Res.,
July 1, 2008;
14(13):
4119 - 4127.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Oberlin, A. Rey, E. Lyden, G. Bisogno, M. C.G. Stevens, W. H. Meyer, M. Carli, and J. R. Anderson
Prognostic Factors in Metastatic Rhabdomyosarcomas: Results of a Pooled Analysis From United States and European Cooperative Groups
J. Clin. Oncol.,
May 10, 2008;
26(14):
2384 - 2389.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
O. Slater and J. Shipley
Clinical relevance of molecular genetics to paediatric sarcomas
J. Clin. Pathol.,
November 1, 2007;
60(11):
1187 - 1194.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. M. Linardic, S. Naini, J. E. Herndon II, C. Kesserwan, S. J. Qualman, and C. M. Counter
The PAX3-FKHR Fusion Gene of Rhabdomyosarcoma Cooperates with Loss of p16INK4A to Promote Bypass of Cellular Senescence
Cancer Res.,
July 15, 2007;
67(14):
6691 - 6699.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. Vassal, D. Couanet, E. Stockdale, A. Geoffray, B. Geoerger, D. Orbach, F. Pichon, J. C. Gentet, S. Picton, C. Bergeron, et al.
Phase II Trial of Irinotecan in Children With Relapsed or Refractory Rhabdomyosarcoma: A Joint Study of the French Society of Pediatric Oncology and the United Kingdom Children's Cancer Study Group
J. Clin. Oncol.,
February 1, 2007;
25(4):
356 - 361.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. S. Pappo, E. Lyden, P. Breitfeld, S. S. Donaldson, E. Wiener, D. Parham, K. R. Crews, P. Houghton, and W. H. Meyer
Two Consecutive Phase II Window Trials of Irinotecan Alone or in Combination With Vincristine for the Treatment of Metastatic Rhabdomyosarcoma: The Children's Oncology Group
J. Clin. Oncol.,
February 1, 2007;
25(4):
362 - 369.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Davicioni, F. Graf Finckenstein, V. Shahbazian, J. D. Buckley, T. J. Triche, and M. J. Anderson
Identification of a PAX-FKHR Gene Expression Signature that Defines Molecular Classes and Determines the Prognosis of Alveolar Rhabdomyosarcomas.
Cancer Res.,
July 15, 2006;
66(14):
6936 - 6946.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. Saab, J. L. Bills, A. P. Miceli, C. M. Anderson, J. D. Khoury, D. W. Fry, F. Navid, P. J. Houghton, and S. X. Skapek
Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells
Mol. Cancer Ther.,
May 1, 2006;
5(5):
1299 - 1308.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. Gattenlohner, A. Marx, B. Markfort, S. Pscherer, S. Landmeier, H. Juergens, H.-K. Muller-Hermelink, I. Matthews, D. Beeson, A. Vincent, et al.
Rhabdomyosarcoma Lysis by T Cells Expressing a Human Autoantibody-Based Chimeric Receptor Targeting the Fetal Acetylcholine Receptor
Cancer Res.,
January 1, 2006;
66(1):
24 - 28.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
S. L. Spunt, T. A. Sweeney, M. M. Hudson, C. A. Billups, M. J. Krasin, and A. L. Hester
Late Effects of Pelvic Rhabdomyosarcoma and Its Treatment in Female Survivors
J. Clin. Oncol.,
October 1, 2005;
23(28):
7143 - 7151.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Carli, R. Colombatti, O. Oberlin, G. Bisogno, J. Treuner, E. Koscielniak, G. Tridello, A. Garaventa, R. Pinkerton, and M. Stevens
European Intergroup Studies (MMT4-89 and MMT4-91) on Childhood Metastatic Rhabdomyosarcoma: Final Results and Analysis of Prognostic Factors
J. Clin. Oncol.,
December 1, 2004;
22(23):
4787 - 4794.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. O. Walterhouse, E. R. Lyden, P. P. Breitfeld, S. J. Qualman, M. D. Wharam, and W. H. Meyer
Efficacy of Topotecan and Cyclophosphamide Given in a Phase II Window Trial in Children With Newly Diagnosed Metastatic Rhabdomyosarcoma: A Children's Oncology Group Study
J. Clin. Oncol.,
April 15, 2004;
22(8):
1398 - 1403.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
